Results 1 to 10 of about 806,554 (265)

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus [PDF]

open access: yesDiabetes & Metabolism Journal, 2021
We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n ...
Soon-Jib Yoo   +8 more
doaj   +1 more source

Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus

open access: yesFrontiers in Pharmacology, 2021
Mycobacterium abscessus is a difficult respiratory pathogen to treat, when compared to other nontuberculus mycobacteria (NTM), due to its drug resistance.
Bui Thi Bich Hanh   +7 more
doaj   +1 more source

Basic principles of combination therapy: focus on drug-drug interaction

open access: yesКардиоваскулярная терапия и профилактика, 2021
The article is devoted to the issue of drug interactions in the combination regimens. Today, when drug therapy is the first-line approach for patients with noncommunicable diseases, and the world population ageing leads to an increase in the number of ...
S. Yu. Martsevich   +2 more
doaj   +1 more source

Potential drug interactions in adults living in the Brazilian Amazon: A population-based case-control study, 2019

open access: yesExploratory Research in Clinical and Social Pharmacy, 2021
Background: Drug interactions are important causes of adverse events. Assessments of pharmacological interactions outside healthcare services settings are scarce. Objective: To assess the frequency and factors associated with these potential interactions
Tayanny Margarida Menezes Almeida Biase   +2 more
doaj   +1 more source

Amphiphilic photosensitizer polymer as a nanocarrier of cytotoxic molecule for carrier‐free combination therapy

open access: yesMedComm – Biomaterials and Applications, 2023
Various nanocarriers have been explored to deliver drugs for combination therapy. However, most nanocarriers are composed of inert materials without contribution for improving the cancer therapeutic effect.
Jingqi Xin   +3 more
doaj   +1 more source

Tools to develop antibiotic combinations that target drug tolerance in Mycobacterium tuberculosis

open access: yesFrontiers in Cellular and Infection Microbiology, 2023
Combination therapy is necessary to treat tuberculosis to decrease the rate of disease relapse and prevent the acquisition of drug resistance, and shorter regimens are urgently needed.
Talia Greenstein   +5 more
doaj   +1 more source

Understanding and targeting resistance mechanisms in cancer

open access: yesMedComm, 2023
Resistance to cancer therapies has been a commonly observed phenomenon in clinical practice, which is one of the major causes of treatment failure and poor patient survival. The reduced responsiveness of cancer cells is a multifaceted phenomenon that can
Zi‐Ning Lei   +6 more
doaj   +1 more source

Nanoparticles for Combination Drug Therapy [PDF]

open access: yesACS Nano, 2013
Nanoparticles have recently emerged as a promising class of carriers for the co-delivery of multiple drugs. Combination therapies of small-molecule drugs are common in clinical practice, and it is anticipated that packaging into single macromolecular carriers will enable drug release in precisely balanced ratios and rates and in selectively targeted ...
Liang, Ma, Manish, Kohli, Andrew, Smith
openaire   +2 more sources

High Drug-Loading Nanomedicines for Tumor Chemo–Photo Combination Therapy: Advances and Perspectives

open access: yesPharmaceutics, 2022
The combination of phototherapy and chemotherapy (chemo–photo combination therapy) is an excellent attempt for tumor treatment. The key requirement of this technology is the high drug-loading nanomedicines, which can load either chemotherapy drugs or ...
Ya Wang   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy